Benzothiazol-one Allosteric Modulators for mGluR2 Selectivity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for neurological and psychiatric disorders associated with glutamate dysfunction lack effective modulation of metabotropic glutamate receptors, particularly the mGluR2 receptor, which are implicated in various neurological and psychiatric disorders.

Innovation Solution

Development of benzothiazol-one and thiazolo pyridine derivatives that act as potentiators of metabotropic glutamate receptors, specifically mGluR2 receptors, enhancing the receptor's response to endogenous glutamate without binding to the orthosteric site, thereby offering a distinct pharmacological profile and potential therapeutic benefit.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments are used for neurological and psychiatric disorders associated with glutamate dysfunction, then existing therapies can be administered, but effective modulation of metabotropic glutamate receptors particularly mGluR2 is not achieved

Engineering Contradiction:

Improveeffectiveness of glutamate receptor modulationVSAvoidpharmacological specificity for mGluR2

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent modifies the molecular structure of glutamate receptor modulators by changing chemical parameters - specifically incorporating benzothiazol-one and thiazolo pyridine derivative structures with specific substituents (R1-R6 groups) to achieve selective mGluR2 modulation. This structural parameter change enables effective and specific receptor modulation that conventional treatments lack.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces positive allosteric modulators as intermediary substances that bind to allosteric sites on the mGluR2 receptor (not the orthosteric glutamate binding site) to enhance receptor activity. These modulators act as mediators that amplify the effect of endogenous glutamate without directly activating the receptor, providing selective and effective modulation.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If positive allosteric modulators bind to the orthosteric site, then direct activation occurs, but pharmacological specificity and distinct profile are limited

Engineering Contradiction:

Improvereceptor activation effectivenessVSAvoidpharmacological profile distinction

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent employs positive allosteric modulators that bind to allosteric sites (distinct from the orthosteric glutamate binding site) on the mGluR2 receptor. This intermediary binding approach allows the modulators to enhance receptor activity through a different mechanism, providing pharmacological specificity and a distinct profile compared to direct orthosteric activation.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent separates the binding site into two distinct locations: the orthosteric site for endogenous glutamate and the allosteric site for the modulator. This segmentation allows independent optimization of each site's interaction, enabling selective mGluR2 modulation with a distinct pharmacological profile that differs from conventional direct agonists.

Inventive Principle:

Principle #1Segmentation

3Reliability

If non-selective mGluR2/mGluR3 agonists are used, then efficacy in animal models is achieved, but selectivity and therapeutic precision are reduced

Engineering Contradiction:

Improveefficacy in disease modelsVSAvoidreceptor selectivity

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies local quality by designing modulators with specific structural features (benzothiazol-one and thiazolo pyridine cores with particular substituent patterns) that confer selective affinity for mGluR2 over mGluR3 and other glutamate receptors. This localized structural optimization at the binding site enables selective receptor activation while maintaining efficacy in disease models.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent utilizes parameter changes in the molecular structure - specifically the chemical substituents (R1-R6 groups including alkyl, aryl, heterocyclic, and functional groups) - to fine-tune receptor selectivity. By adjusting these structural parameters, the modulators achieve high selectivity for mGluR2 while maintaining the efficacy demonstrated in animal models of neurological and psychiatric disorders.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS8952005B2Substituted 1,3-benzothiazol-2(3H)-ones and [1,3]thiazolo[5,4-B]pyridin-2(1H)-ones as positive allosteric modulators of mGluR2

Publication Date: 2015.02.10 MERCK SHARP & DOHME LLC

AI summary

The present invention is directed to benzothiazol-one and thiazolo pyridine-one derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.